These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37093910)

  • 1. Effectiveness of Pegylated Interferon Alpha-2a in Post-Uveitic Macular Edema Previously Responding to Non-Pegylated Interferon.
    De Simone L; Gentile P; Aldigeri R; Mastrofilippo V; Bolletta E; Gozzi F; Adani C; Salvarani C; Cimino L
    Ocul Immunol Inflamm; 2024 Jul; 32(5):678-682. PubMed ID: 37093910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon Alpha-2a Treatment for Post-Uveitic Refractory Macular Edema.
    De Simone L; Sangiovanni A; Aldigeri R; Mastrofilippo V; Bolletta E; Invernizzi A; Fares L; Pipitone N; Fontana L; Salvarani C; Cimino L
    Ocul Immunol Inflamm; 2020; 28(2):322-328. PubMed ID: 31107604
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of Refractory Cystoid Macular Edema with Pegylated Interferon Alfa-2A: A Retrospective Chart Review.
    Stiefel HC; Kopplin LJ; Albini T; Chang M; Vegunta S; Suhler EB
    Ocul Immunol Inflamm; 2021 Apr; 29(3):566-571. PubMed ID: 31743052
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and Safety of Interferon Alpha 2A and Pegylated Interferon Alpha 2A in Inflammatory Macular Edema.
    Couret C; Servant M; Lebranchu P; Hamidou M; Weber M
    Ocul Immunol Inflamm; 2020; 28(2):329-336. PubMed ID: 31821064
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of Pegylated Interferon Alpha-2a in Uveitic Macular Edema Refractory to Biologic Agents.
    Avarand M; Esen Baris M; Taheri L; Guven Yılmaz S
    Ocul Immunol Inflamm; 2023 Dec; 31(10):1900-1905. PubMed ID: 37917790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of Treatment of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial 2-Year Results.
    Tomkins-Netzer O; Lightman S; Drye L; Kempen J; Holland GN; Rao NA; Stawell RJ; Vitale A; Jabs DA;
    Ophthalmology; 2015 Nov; 122(11):2351-9. PubMed ID: 26359188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up.
    Cervantes-Castañeda RA; Giuliari GP; Gallagher MJ; Yilmaz T; MacDonell RE; Quinones K; Foster CS
    Eur J Ophthalmol; 2009; 19(4):622-9. PubMed ID: 19551679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive topical interferon therapy in uveitic macular edema.
    Kawali A; Sanjay S; Mohan A; Mahendradas P; Shroff S; Shetty R
    Indian J Ophthalmol; 2022 Aug; 70(8):2986-2989. PubMed ID: 35918958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spectral domain optical coherence tomography changes following intravitreal dexamethasone implant, Ozurdex® in patients with uveitic cystoid macular edema.
    Bansal P; Agarwal A; Gupta V; Singh R; Gupta A
    Indian J Ophthalmol; 2015 May; 63(5):416-22. PubMed ID: 26139803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon Alpha for the Treatment of Cystoid Macular Edema Associated with Presumed Ocular Tuberculosis.
    Oray M; Onal S; Uludag G; Akbay AK; Tugal-Tutkun I
    J Ocul Pharmacol Ther; 2017 May; 33(4):304-312. PubMed ID: 28414561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavior of hyperreflective foci in non-infectious uveitic macular edema, a 12-month follow-up prospective study.
    Berasategui B; Fonollosa A; Artaraz J; Ruiz-Arruza I; Ríos J; Matas J; Llorenç V; Diaz-Valle D; Sastre-Ibañez M; Arriola-Villalobos P; Adan A
    BMC Ophthalmol; 2018 Jul; 18(1):179. PubMed ID: 30029623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seven-Year Outcomes of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial and Follow-up Study Results.
    Tomkins-Netzer O; Lightman SL; Burke AE; Sugar EA; Lim LL; Jaffe GJ; Altaweel MM; Kempen JH; Holbrook JT; Jabs DA;
    Ophthalmology; 2021 May; 128(5):719-728. PubMed ID: 32918964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visual Acuity in Retinal Vein Occlusion, Diabetic, and Uveitic Macular Edema: Central Subfield Thickness and Ellipsoid Zone Analysis.
    Ciulla TA; Kapik B; Grewal DS; Ip MS
    Ophthalmol Retina; 2021 Jul; 5(7):633-647. PubMed ID: 33130256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Efficacy of Pegylated Interferon Alpha-2b in Behçet's Uveitis: A Small Case Series.
    Celiker H; Kazokoglu H; Direskeneli H
    Ocul Immunol Inflamm; 2019; 27(1):15-22. PubMed ID: 28700247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China.
    Hu Y; Ye YZ; Ye LJ; Wang XH; Yu H
    World J Pediatr; 2019 Dec; 15(6):595-600. PubMed ID: 31487005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up.
    Arevalo JF; Sanchez JG; Fromow-Guerra J; Wu L; Berrocal MH; Farah ME; Cardillo J; Rodríguez FJ;
    Graefes Arch Clin Exp Ophthalmol; 2009 Jun; 247(6):735-43. PubMed ID: 19189118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study.
    Deuter CM; Koetter I; Guenaydin I; Stuebiger N; Zierhut M
    Retina; 2006 Sep; 26(7):786-91. PubMed ID: 16963852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The efficacy and safety of subconjunctival triamcinolone acetonide injections in treatment of uveitic macular edema].
    Liu X; Wang M; Zhao C; Gao F; Zhang M
    Zhonghua Yan Ke Za Zhi; 2015 Oct; 51(10):734-8. PubMed ID: 26693767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial.
    Thorne JE; Sugar EA; Holbrook JT; Burke AE; Altaweel MM; Vitale AT; Acharya NR; Kempen JH; Jabs DA;
    Ophthalmology; 2019 Feb; 126(2):283-295. PubMed ID: 30269924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion.
    Jaissle GB; Szurman P; Feltgen N; Spitzer B; Pielen A; Rehak M; Spital G; Heimann H; Meyer CH;
    Graefes Arch Clin Exp Ophthalmol; 2011 Feb; 249(2):183-92. PubMed ID: 21337042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.